Grufity logoGrufity logo
StocksFundsSearch Filings

Mersana Therapeutics Inc Stock Research

MRSN

7.50USD+0.43(+6.08%)Market Closed

Market Summary

USD7.50+0.43
Market Closed
6.08%

MRSN Alerts

MRSN Stock Price

MRSN RSI Chart

MRSN Valuation

Market Cap

771.1M

Price/Earnings (Trailing)

-3.62

Price/Sales (Trailing)

23.84

Price/Free Cashflow

-10.53

MRSN Price/Sales (Trailing)

MRSN Profitability

Return on Equity

-221.82%

Return on Assets

-61.08%

Free Cashflow Yield

-9.49%

MRSN Fundamentals

MRSN Revenue

Revenue (TTM)

32.3M

Revenue Y/Y

1.3K%

Revenue Q/Q

163.56%

MRSN Earnings

Earnings (TTM)

-213.1M

Earnings Y/Y

-18.92%

Earnings Q/Q

-25.17%

Price Action

52 Week Range

2.928.39
(Low)(High)

Last 7 days

-6.4%

Last 30 days

61.4%

Last 90 days

21.7%

Trailing 12 Months

112.3%

MRSN Financial Health

Current Ratio

3.49

Debt/Equity

0.27

Debt/Cashflow

-1.99

MRSN Investor Care

Shares Dilution (1Y)

25.25%

Diluted EPS (TTM)

-2.11

Peers (Alternatives to Mersana Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
311.1B
1.6B
-10.47% 70.40%
-162.26
199.76
77.54% 1.62%
285.4B
56.7B
-9.71% -7.25%
24.12
4.92
0.03% -39.22%
87.6B
12.4B
-9.13% 5.17%
20.2
7.2
-25.07% -47.28%
83.8B
9.2B
-4.53% 18.84%
25.7
9.1
15.86% 32.99%
23.2B
1.0B
-6.40% 45.93%
-21.75
22.33
22.88% -19.27%
11.6B
975.7M
1.67% 67.21%
-10.42
11.92
27.41% -212.78%
9.6B
2.0B
-10.84% -12.99%
13.17
4.84
12.05% 52.86%
MID-CAP
5.1B
-
-10.25% 307.66%
-16.27
2.5K
- -27.52%
3.4B
204.6M
10.50% 0.21%
-5.87
16.66
-7.52% 10.65%
3.4B
363.3M
10.85% -0.47%
-4.8
9.35
3.39% -55.81%
2.2B
18.9M
-16.27% -6.81%
-2.93
114.18
- -16.17%
SMALL-CAP
3.6B
-
1.50% -9.34%
-8.36
38.06
34.30% -67.22%
1.2B
256.5M
-27.45% 57.57%
12.31
4.77
66.85% 120.61%
288.8M
165.3M
-32.22% 33.43%
-3.16
1.75
130.70% 57.97%
37.4M
-
1.03% 2894.60%
-0.74
19.11
- -29.84%

Financials for Mersana Therapeutics

Income Statement (Last 12 Months)
(In Thousands)
* denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue21.7%32,34726,58115,85712,6408,144
Operating Expenses7.4%247,363230,348217,876198,063182,867
  S&GA Expenses9.7%62,50956,96352,83248,38342,463
  R&D Expenses6.6%184,854173,385165,044149,680140,404
Interest Expenses7.8%3,5873,3283,3452,5631,898
Net Income-4.4%-213,119-204,200-208,277-193,977-182,671
Net Income Margin41.5%-7.68*-13.13*-4.41--
Free Cahsflow-22.5%-51,560-42,101-132,416-121,784-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-11.4%296334315252258
  Current Assets-11.7%282319300237241
    Cash Equivalents-4.3%123129184135230
  Net PPE-4.00----
Liabilities-4.3%232242225118118
  Current Liabilities-8.9%83.0092.0089.0071.0056.00
  Long Term Debt0.3%25.0025.0025.00--
    LT Debt, Non Current0.3%25.0025.00---
Shareholder's Equity-30.2%64.0092.0090.00134141
  Retained Earnings-8.6%-710-654-609-549-497
  Additional Paid-In Capital3.8%775747700684638
Shares Outstanding3.7%10910599.0097.0087.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-42.6%-70.41-49.36-40.53-131-120
  Share Based Compensation4.3%22.0022.0021.0021.0020.00
Cashflow From Investing1.1%-150-152-107-91.00-0.86
Cashflow From Financing-25.4%114153140130124

Risks for MRSN

What is the probability of a big loss on MRSN?

100%


Probability that Mersana Therapeutics stock will be more than 20% underwater in next one year

100%


Probability that Mersana Therapeutics stock will be more than 30% underwater in next one year.

94.2%


Probability that Mersana Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MRSN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Mersana Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for MRSN

Cumulative Returns on MRSN

-19.5%


5-Year Cumulative Returns

-32.2%


3-Year Cumulative Returns

What are the long-term rolling returns for MRSN?

FIve years rolling returns for Mersana Therapeutics.

Annualized Returns

Which funds bought or sold MRSN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-26
ProShare Advisors LLC
reduced
-8.82
-42,593
75,550
-%
2023-05-22
AMERIPRISE FINANCIAL INC
sold off
-100
-158,000
-
-%
2023-05-18
JPMORGAN CHASE & CO
reduced
-68.57
-1,767,000
500,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-33.71
-175,000
153,000
-%
2023-05-17
Thrivent Financial for Lutherans
unchanged
-
-107,000
250,000
-%
2023-05-16
FRED ALGER MANAGEMENT, LLC
sold off
-100
-2,217,720
-
-%
2023-05-16
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
586
893,196
1,127,320
-%
2023-05-16
Hudson Bay Capital Management LP
added
132
1,018,900
2,630,400
0.01%
2023-05-15
TWO SIGMA SECURITIES, LLC
sold off
-100
-89,224
-
-%
2023-05-15
Royal Bank of Canada
reduced
-60.32
-55,000
21,000
-%

1–10 of 44

Latest Funds Activity

Are funds buying MRSN calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own MRSN
No. of Funds

Mersana Therapeutics News

The Dwinnex
8 analysts offer recommendations for Mersana Therapeutics Inc ....
The Dwinnex,
5 hours ago

Schedule 13G FIlings of Mersana Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
bb biotech ag
4.1%
4,066,200
SC 13G/A
Feb 14, 2023
avoro capital advisors llc
7.6%
7,550,000
SC 13G/A
Feb 14, 2023
rho ventures v, l.p.
0%
0
SC 13G/A
Feb 14, 2023
orbimed advisors llc
7.1%
7,082,837
SC 13G
Feb 09, 2023
vanguard group inc
4.46%
4,449,040
SC 13G/A
Feb 06, 2023
wellington management group llp
0.00%
0
SC 13G/A
Feb 03, 2023
state street corp
5.87%
5,856,061
SC 13G/A
Jan 31, 2023
blackrock inc.
7.5%
7,491,929
SC 13G/A
Jan 19, 2023
millennium management llc
3.7%
3,663,527
SC 13G/A
May 11, 2022
bain capital life sciences fund ii, l.p.
3.4%
3,294,423
SC 13D/A

MRSN Fair Value

Show Fair-Value

Recent SEC filings of Mersana Therapeutics

View All Filings
Date Filed Form Type Document
May 09, 2023
10-Q
Quarterly Report
May 09, 2023
8-K
Current Report
May 09, 2023
S-3ASR
S-3ASR
Apr 28, 2023
4
Insider Trading
Apr 28, 2023
ARS
ARS
Apr 28, 2023
DEF 14A
DEF 14A
Apr 28, 2023
DEFA14A
DEFA14A
Apr 14, 2023
PRE 14A
PRE 14A
Apr 05, 2023
4
Insider Trading
Apr 05, 2023
4
Insider Trading

Latest Insider Trading transactions for MRSN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-04-27
Carvajal Alejandra
sold
-15,342
3.89
-3,944
svp, chief legal officer
2023-04-26
Carvajal Alejandra
acquired
-
-
13,250
svp, chief legal officer
2023-04-03
MOTT DAVID M
acquired
-
-
4,866
-
2023-04-03
Dere Willard H
acquired
-
-
3,375
-
2023-01-17
Carvajal Alejandra
sold
-4,488
5.74
-782
svp, chief legal officer
2023-01-17
Mandelia Ashish
sold
-20,520
5.74
-3,575
vp, controller
2023-01-17
Protopapas Anna
sold
-99,566
5.74
-17,346
president & ceo
2023-01-17
MISRA TUSHAR
sold
-2,628
5.74
-458
svp, cmo
2023-01-17
Lowinger Timothy B
sold
-35,777
5.74
-6,233
svp, chief sci.&tech. off.
2023-01-17
DeSchuytner Brian
sold
-29,451
5.74
-5,131
svp, chief financial officer

1–10 of 50

About Mersana Therapeutics

Anna Protopapas
170
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

MRSN Income Statement

2023-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]  
Collaboration revenue$ 7,802$ 2,036
Operating expenses:  
Research and development47,27535,806
General and administrative18,32812,782
Total operating expenses65,60348,588
Other income (expense):  
Interest income2,62118
Interest expense(983)(724)
Total other income (expense), net1,638(706)
Net loss(56,163)(47,258)
Unrealized gain on marketable securities1640
Comprehensive loss(55,999)(47,258)
Net loss attributable to common stockholders — basic(56,163)(47,258)
Net loss attributable to common stockholders — diluted$ (56,163)$ (47,258)
Net loss per share attributable to common stockholders — basic (in dollars per share)$ (0.52)$ (0.59)
Net loss per share attributable to common stockholders — diluted (in dollars per share)$ (0.52)$ (0.59)
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — basic (in shares)107,514,65579,928,591
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — diluted (in shares)107,514,65579,928,591

MRSN Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 122,825$ 128,885
Short-term marketable securities151,094151,827
Accounts receivable030,000
Prepaid expenses and other current assets7,8888,507
Total current assets281,807319,219
Property and equipment, net3,9943,985
Operating lease right-of-use assets9,80610,475
Other assets, noncurrent588661
Total assets296,195334,340
Current liabilities:  
Accounts payable18,15613,951
Accrued expenses32,58843,184
Deferred revenue28,76930,610
Operating lease liabilities2,9042,798
Other current liabilities985990
Total current liabilities83,40291,533
Operating lease liabilities, noncurrent7,7738,575
Long-term debt, net25,00424,929
Deferred revenue, noncurrent115,582117,043
Other liabilities, noncurrent140203
Total liabilities231,901242,283
Commitments (Note 11)
Stockholders' equity:  
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively00
Common stock, $0.0001 par value; 350,000,000 shares authorized; 109,061,074 and 105,144,864 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively1111
Additional paid-in capital775,125746,889
Accumulated other comprehensive income (loss)12(152)
Accumulated deficit(710,854)(654,691)
Total stockholders’ equity64,29492,057
Total liabilities and stockholders’ equity$ 296,195$ 334,340